NO901139L - PROCEDURE FOR AA PREVENTING THE EXPOSURE OF METAL IONES FROM THEIR Aqueous SOLUTIONS. - Google Patents
PROCEDURE FOR AA PREVENTING THE EXPOSURE OF METAL IONES FROM THEIR Aqueous SOLUTIONS.Info
- Publication number
- NO901139L NO901139L NO901139A NO901139A NO901139L NO 901139 L NO901139 L NO 901139L NO 901139 A NO901139 A NO 901139A NO 901139 A NO901139 A NO 901139A NO 901139 L NO901139 L NO 901139L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- formula
- metal
- solution
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 10
- 239000007864 aqueous solution Substances 0.000 title claims description 3
- 239000002184 metal Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 12
- -1 amine salts Chemical class 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 5
- 229910021645 metal ion Inorganic materials 0.000 claims description 5
- 150000003007 phosphonic acid derivatives Chemical class 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- 229940042400 direct acting antivirals phosphonic acid derivative Drugs 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 210000000988 bone and bone Anatomy 0.000 description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 13
- 150000001412 amines Chemical class 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 238000012800 visualization Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000536 complexating effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 229940102859 methylene diphosphonate Drugs 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- LTYRAPJYLUPLCI-UHFFFAOYSA-N glycolonitrile Chemical compound OCC#N LTYRAPJYLUPLCI-UHFFFAOYSA-N 0.000 description 3
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- CIOAGBVUUVVLOB-OIOBTWANSA-N strontium-85 Chemical compound [85Sr] CIOAGBVUUVVLOB-OIOBTWANSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000003956 methylamines Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000002847 norbornane derivatives Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 229940048084 pyrophosphate Drugs 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940056501 technetium 99m Drugs 0.000 description 2
- VPTUPAVOBUEXMZ-UHFFFAOYSA-N (1-hydroxy-2-phosphonoethyl)phosphonic acid Chemical compound OP(=O)(O)C(O)CP(O)(O)=O VPTUPAVOBUEXMZ-UHFFFAOYSA-N 0.000 description 1
- CKDSFRWKHBYHHT-UHFFFAOYSA-N 4-bicyclo[2.2.1]heptanylmethanamine Chemical compound C1CC2CCC1(CN)C2 CKDSFRWKHBYHHT-UHFFFAOYSA-N 0.000 description 1
- YXTDAZMTQFUZHK-UHFFFAOYSA-L 5,6-dihydroxy-1,3,2$l^{2}-dioxastannepane-4,7-dione Chemical class [Sn+2].[O-]C(=O)C(O)C(O)C([O-])=O YXTDAZMTQFUZHK-UHFFFAOYSA-L 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- HWZUDASOMGNLSM-UHFFFAOYSA-N O=P1OCOP(=O)O1 Chemical compound O=P1OCOP(=O)O1 HWZUDASOMGNLSM-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- YDONNITUKPKTIG-UHFFFAOYSA-N [Nitrilotris(methylene)]trisphosphonic acid Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CP(O)(O)=O YDONNITUKPKTIG-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical class 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- VBJYLXXUKGFOBL-UHFFFAOYSA-N bicyclo[2.2.1]heptane;methanamine Chemical compound NC.NC.C1CC2CCC1C2 VBJYLXXUKGFOBL-UHFFFAOYSA-N 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical class C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- HJZKOAYDRQLPME-UHFFFAOYSA-N oxidronic acid Chemical compound OP(=O)(O)C(O)P(O)(O)=O HJZKOAYDRQLPME-UHFFFAOYSA-N 0.000 description 1
- 229960004230 oxidronic acid Drugs 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical class C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 239000002455 scale inhibitor Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- CVKJXWOUXWRRJT-UHFFFAOYSA-N technetium dioxide Chemical compound O=[Tc]=O CVKJXWOUXWRRJT-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- FUIZKNBTOOKONL-DPSBJRLESA-K trisodium;5-[(e)-(3-carboxy-5-methyl-4-oxocyclohexa-2,5-dien-1-ylidene)-(2,6-dichloro-3-sulfonatophenyl)methyl]-3-methyl-2-oxidobenzoate Chemical compound [Na+].[Na+].[Na+].C1=C(C([O-])=O)C(=O)C(C)=C\C1=C(C=1C(=C(C=CC=1Cl)S([O-])(=O)=O)Cl)\C1=CC(C)=C(O)C(C([O-])=O)=C1 FUIZKNBTOOKONL-DPSBJRLESA-K 0.000 description 1
Landscapes
- Preventing Corrosion Or Incrustation Of Metals (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
Description
Norbornan er en cyklisk forbindelse som finnes i eller kan avledes fra de gjenværende tunge hydrokarboner i bunnen av de-stillasjonstårn i anlegg for fremstilling av lette hydrkarboner. En rekke derivater av norbornan er fremstilt, mellom dem bis(metylaminet). Det er denne forbindelsen som er fosfono-metylert som er emne for den foreliggende oppfinnelse. Norbornane is a cyclic compound that is found in or can be derived from the remaining heavy hydrocarbons at the bottom of distillation towers in plants for the production of light hydrocarbons. A number of derivatives of norbornane have been prepared, among them bis(methylamine). It is this compound which is phosphono-methylated which is the subject of the present invention.
Det er vel kjent at aminer, såsom etylendiamin og dietylen-triamin kan omsettes med formaldehyd og fosforsyre slik at det dannes metylenfosfonatderivater av aminet hvori metylenfosfonat-gruppen It is well known that amines, such as ethylenediamine and diethylenetriamine can be reacted with formaldehyde and phosphoric acid so that methylenephosphonate derivatives of the amine are formed in which the methylenephosphonate group
erstatter aminhydrogenene (U.S. 3.288.846) . replacing the amine hydrogens (U.S. 3,288,846) .
Bruken av metylenfosfonsyre-substituerte alkylenpolyaminer til kontroll av metallioner i mindre enn støkiometriske mengder, ble foreslått i et patent (U.S. 2.609.390) utferdiget i 1952. Senere ble et polymert amin som danner chelater, som kan spres med vann, og som inneholder alkylenfos fonatderivater angitt å The use of methylenephosphonic acid-substituted alkylene polyamines to control metal ions in less than stoichiometric amounts was suggested in a patent (U.S. 2,609,390) issued in 1952. Later, a chelating, water-dispersible polymeric amine containing alkylene phos phonate derivatives indicated to
ha "terskel"-virkning i preparater for å hindre kjelesten (se U.S. 3 . 331.773) , dette uttrykket brukes for å beskrive bruken have a "threshold" effect in preparations to prevent gallstones (see U.S. 3 . 331,773), this term is used to describe the use
av midlet i mindre enn støkiometriske mengder. Diamin- og polyamin-metylenfos fonat-derivater omtales og kreves patentert i henholdsvis U.S. 3.336.221 og 3.434.9 69. Noen av produktene omtalt i disse to patentene er tilgjengelige kommersielt, og er anbefalt som midler for å hindre kjelesten når de brukes i terskelmengder. of the agent in less than stoichiometric amounts. Diamine and polyamine methylenephosphonate derivatives are disclosed and claimed in U.S. Pat. 3,336,221 and 3,434,9 69. Some of the products disclosed in these two patents are available commercially, and are recommended as agents to prevent boiler scale when used in threshold amounts.
Andre patenter som omtaler heterocykliske forbindelser som inneholder nitrogen og som er nyttige som chelaterende midler og kan brukes i terskelmengder erU.S. 3.674.804; 3.720.498; 3.743.603; 3.859.211 og 3.954.761. Noen av forbindelsene som er inkludert deri er heterocykliske forbindelser som har formlene: Other patents that discuss nitrogen-containing heterocyclic compounds that are useful as chelating agents and can be used in threshold amounts are U.S. Pat. 3,674,804; 3,720,498; 3,743,603; 3,859,211 and 3,954,761. Some of the compounds included therein are heterocyclic compounds having the formulas:
hvori R er hydrogen eller alkyl og M er hydrogen, alkalimetall, ammonium- eller et di- eller trietanolamin-radikal; Visse fosfonsyrederivater av de alifatiske syrer kan fremstilles ved å omsette fosforsyre med syreanhydrider eller syre-kxorider, f.eks. anhydridene eller kloridene av eddik-, propion-og valeriansyre. Forbindelsene som fremstilles har formelen hvori R er et lavere alkylradikal som har 1 til 5 karbonatomer. Fremgangsmåten for fremstilling og bruk av disse produktene er beskrevet i U.S. 3.214.454. Bruken av terskelmengder for å forhindre kalsiumutfelling er beskrevet og krevd patentert deri. Det er nå oppdaget at nye chelatdannende midler og terskel-midler for å forhindre utfelling av metallioner kan lages ut fra bis(metylamin)derivatene av norbornan. Denne forbindelsen har strukturen wherein R is hydrogen or alkyl and M is hydrogen, alkali metal, ammonium or a di- or triethanolamine radical; Certain phosphonic acid derivatives of the aliphatic acids can be prepared by reacting phosphoric acid with acid anhydrides or acid oxides, e.g. the anhydrides or chlorides of acetic, propionic and valeric acids. The compounds produced have the formula wherein R is a lower alkyl radical having 1 to 5 carbon atoms. The procedure for the manufacture and use of these products is described in U.S. Pat. 3,214,454. The use of threshold amounts to prevent calcium precipitation is described and patented therein. It has now been discovered that new chelating agents and threshold agents to prevent precipitation of metal ions can be made from the bis(methylamine) derivatives of norbornane. This compound has the structure
Denne forbindelsen er ogsa kjent ved det mer formelle navn 2(3), 5 ( 6)-bis [aminometyl] bicyklo ( 2 , 2 ,1) heptan . Dets derivater er de som har forskjellige substituenter som erstatter de primære amin-hydrogener. This compound is also known by the more formal name 2(3), 5 (6)-bis [aminomethyl] bicyclo (2, 2,1) heptane. Its derivatives are those that have different substituents replacing the primary amine hydrogens.
En ny type forbindelser dannes når norbornan bis(metylamin) omsettes med visse forbindelser, f.eks. vil formaldehyd og fosforsyre gi metylenfos fonsyrederivater. Disse nye forbindelsene har strukturen A new type of compound is formed when norbornane bis(methylamine) reacts with certain compounds, e.g. formaldehyde and phosphoric acid will give methylphosphonic acid derivatives. These new compounds have the structure
hvori substituentene A, B, X og Y alle er uavhengig valgt blandt radikaler som består av hydrogen, hydroksyalky1 (hvori alkyl- wherein the substituents A, B, X and Y are all independently selected from radicals consisting of hydrogen, hydroxyalkyl1 (wherein alkyl-
gruppen inneholder 2-6 karbonatomer) , metylenfos fonsyre-, metylen-, etylen- og propylensulfonsyre-, karboksylsyre-radikaler (som har 2-4 karbonatomer) og alkali- og jordalkali-metaller, ammoniakk og aminsalter av noen av fosfon-, sulfon-eller karboksylsyrederivatene. Minst én av substituentene må være forskjellig fra hydrogen. group contains 2-6 carbon atoms), methylene phosphonic acid, methylene, ethylene and propylene sulphonic acid, carboxylic acid radicals (which have 2-4 carbon atoms) and alkali and alkaline earth metals, ammonia and amine salts of some of phosphonic, sulphonic -or the carboxylic acid derivatives. At least one of the substituents must be different from hydrogen.
Fremgangsmåter for å få hydroksyalkyl-, sulfonsyre- eller karboksylsyrederivater av forbindelser med formel I, er vel kjent innen faget. Methods for obtaining hydroxyalkyl, sulphonic acid or carboxylic acid derivatives of compounds of formula I are well known in the art.
Fremgangsmåten for å substituere et hydrogen i et amin med en hydroksyalkyigruppe ved omsetning med et epoksyd, f.eks. etylen eller propylenoksyd, er vist i U.S. 3.398.198. The process of substituting a hydrogen in an amine with a hydroxyalkyl group by reaction with an epoxide, e.g. ethylene or propylene oxide, is shown in U.S. Pat. 3,398,198.
Sulfonsyreradikaiene kan erstatte et aminhydrogen ved at aminet omsettes med en blanding av natriumbisulfit og formaldehyd for å få en metylensulfonsyregruppe-substituent på nitro-genet i aminforbindelsen. Denne reaksjonen er forklart i "Preparation and Properties ofAminoethylenesulfonic Acids", J.Am. Chem. Soc. 77, 5512-15 (1955). Andre alkylsulfonsyre-derivater kan fremstilles ved å omsette aminet med kloralkyl-s ulfonsyrer. The sulfonic acid radicals can replace an amine hydrogen by reacting the amine with a mixture of sodium bisulfite and formaldehyde to obtain a methylene sulfonic acid group substituent on the nitrogen in the amine compound. This reaction is explained in "Preparation and Properties of Aminoethylenesulfonic Acids", J. Am. Chem. Soc. 77, 5512-15 (1955). Other alkyl sulfonic acid derivatives can be prepared by reacting the amine with chloroalkyl sulfonic acids.
Karboksylsyregruppen kan erstatte et aminhydrogen ved at aminet omsettes i vandig oppløsning med passende nitriler såsom glykolonitri1 og akrylonitril i nærvær av overskudd av kaustisk soda (NaOH) og deretter overføres saltformen av syreradikalet til det fri karboksylsyreradikal i henhold til den velkjente fremgangsmåte. The carboxylic acid group can replace an amine hydrogen by reacting the amine in aqueous solution with suitable nitriles such as glycolinitri1 and acrylonitrile in the presence of an excess of caustic soda (NaOH) and then transferring the salt form of the acid radical to the free carboxylic acid radical according to the well-known method.
Når det gjelder å fremstille aminsalter av syreradikalene, er reaksjonen velkjent. I Richters 3. utgave (1952) av hans "Textbook of Organic Chemistry", side 246, sies det "Aminer av alle typer, på samme måte som ammoniakk, er basiske forbindelser og reagerer lett med syrer og danner ioniserbare salter". When it comes to preparing amine salts from the acid radicals, the reaction is well known. In Richter's 3rd edition (1952) of his "Textbook of Organic Chemistry", page 246, it is stated "Amines of all types, like ammonia, are basic compounds and react readily with acids to form ionizable salts".
Den foreliggende oppfinnelse gjelder også bruken av bis-(aminometyl) bicyklo [2 . 2 . l] heptaner med formel I som kompleksdannende forbindelser for radionuklider når det gjelder å visualisere skjelettsystemet til dyr. The present invention also applies to the use of bis-(aminomethyl) bicyclo [2 . 2. l] heptanes of formula I as complexing compounds for radionuclides when it comes to visualizing the skeletal system of animals.
Den første radionuklide som ble omfattende brukt til ben-scanning, var Sr-85. Strontium-85 akkumuleres raskt i benvev etter intravenøs administrering, og visualisering av skjelettsystemet er mulig. Imidlertid har Sr-85 lang fysisk halverings tid (65 dager) og lang biologisk halveringstid (-800 dager), noe som begrenser mengdene som kan administreres. Dessuten er den høye energien til gammafotonene som emitteres (514 kev) vanske-lig å kollimere. The first radionuclide widely used for bone scanning was Sr-85. Strontium-85 accumulates rapidly in bone tissue after intravenous administration, and visualization of the skeletal system is possible. However, Sr-85 has a long physical half-life (65 days) and a long biological half-life (-800 days), which limits the amounts that can be administered. Moreover, the high energy of the emitted gamma photons (514 kev) is difficult to collimate.
Fiuor-18 er også blitt brukt til å visualisere skjelettsystemet. Det er en positronutstråler med halveringstid 1,85 t. Selv om F-18 har gode fysiske egenskaper for visualisering, har det noen alvorlige ulemper. Fluor-18 fremstilles i cyklotron, og er derfor dyrt. Dessuten er distribueringen begrenset på grunn av den korte halveringstiden. Fiuor-18 has also been used to visualize the skeletal system. It is a positron emitter with a half-life of 1.85 h. Although the F-18 has good physical properties for visualization, it has some serious drawbacks. Fluorine-18 is produced in a cyclotron, and is therefore expensive. Furthermore, the distribution is limited due to the short half-life.
Mange organscanningsmidler, inkludert de til skjelettsystemet, er nå erstattet med komplekser av technetium-99m. Denne nukliden har ideelle fysiske egenskaper (T,=6t, gammafoton 141 kev) for visualisering. I tillegg er den lett tilgjengelig på grunn av Mo-99/Tc-99m-generatorer. Således gjøres nå meste-parten av visualiseringen med bruk av Tc-99m. Many organ scanning agents, including those for the skeletal system, have now been replaced with complexes of technetium-99m. This nuclide has ideal physical properties (T,=6t, gamma photon 141 kev) for visualization. Additionally, it is readily available due to Mo-99/Tc-99m generators. Thus, most of the visualization is now done using Tc-99m.
Technetium-99m kan fåes fra generatorer i + 7 oksydasjonstrinn som pertechnetationet (TcO^ ). For å kunne danne et kompleks må Tc være på et lavere oksydasjonstrinn, f.eks. +3, +4 Technetium-99m can be obtained from generators in + 7 oxidation stages such as the pertechnetation (TcO^ ). To be able to form a complex, Tc must be at a lower oxidation state, e.g. +3, +4
2+ eller +5. Selv om andre reduksjonsmidler kan brukes, er Sn mest vanlig brukt. Således kan Tc-99m-komplekser dannes ved 2+ or +5. Although other reducing agents can be used, Sn is most commonly used. Thus, Tc-99m complexes can be formed by
2+ 2+
reduksjon av TcO^ med bruk av Sn i nærvær av en kompleksdannende forbindelse. Dette utføres vanligvis i en vandig saiinsk oppløsning som er egnet til intravenøs injeksjon. reduction of TcO^ using Sn in the presence of a complexing compound. This is usually carried out in an aqueous saline solution suitable for intravenous injection.
Kompleksdannende forbindelser selges i handelen som "radio f armas øy tiske sett" . Et "sett" består av en evakuert ampulle som inneholder den kompleksdannende forbindelse, et reduksjonsmiddel og muligvis en buffer og stabiliseringsmidler. For å fremstille Tc-99m-kompleksene, injiseres noen få milli-liter natriumperteknetat-oppløsning i saltvannsoppløsning inn i ampullen. En passende mengde av den resulterende oppløsningen brukes til visualiseringen. Complexing compounds are sold in the trade as "radio pharmaceutical kits". A "kit" consists of an evacuated ampoule containing the complexing compound, a reducing agent and possibly a buffer and stabilizing agents. To prepare the Tc-99m complexes, a few milliliters of sodium pertechnetate solution in saline is injected into the vial. An appropriate amount of the resulting solution is used for the visualization.
Subramanion et al (Radiology, Vol. 99, sidene 192-196, 1971). rapporterte bruken av et kompleks av Tc-99m og et inorganisk polyfosfat til skjelettvisualisering. Mange andre har rappor-tert inorganiske polyfosfater som nyttige til dette formål Subramanion et al (Radiology, Vol. 99, pages 192-196, 1971). reported the use of a complex of Tc-99m and an inorganic polyphosphate for skeletal visualization. Many others have reported inorganic polyphosphates as useful for this purpose
(se U.S. 3.852.414; 4.016.249 og 4.082.840). Bruken av pyro-fosfat (PYP) til skjelettvisualisering er også vist (U.S. 3.851.044; 3.931.396 og 4.075.314). Tc-fosfatene hadde ganske (see U.S. 3,852,414; 4,016,249 and 4,082,840). The use of pyro-phosphate (PYP) for skeletal visualization has also been shown (U.S. 3,851,044; 3,931,396 and 4,075,314). The Tc phosphates had quite
5 5
god suksess, men er blitt erstattet med Tc-fosfonater. good success, but has been replaced by Tc-phosphonates.
Komplekser av Tc-99m med fosfonsyre viser større benopptak med raskere blod-clearance enn Tc-99m/fosfat-komplekser. Fos-fonsyrer som er ansett som de beste benscanningsmidler når de har dannet komplekser med Tc-99m, omfatter hydroksyetandifos-fonat (EHDP), metylendifosfonat (MDP) og hydroksymetylendi-fosfonat (se U .S . 3 . 983.227; 3.989.730 ; 4 .032 .625 og også J.Nucl.Med., 21, side 767, Radiology 136, side 209; J.Nucl.Med., 21, side 961; Radiology 136, side 747). Complexes of Tc-99m with phosphonic acid show greater bone uptake with faster blood clearance than Tc-99m/phosphate complexes. Phosphonic acids considered the best bone scan agents when complexed with Tc-99m include hydroxyethanediphosphonate (EHDP), methylenediphosphonate (MDP) and hydroxymethylenediphosphonate (see U.S. 3. 983,227; 3,989,730; 4 .032 .625 and also J.Nucl.Med., 21, page 767, Radiology 136, page 209; J.Nucl.Med., 21, page 961; Radiology 136, page 747).
Nye stabile kompleksdannende forbindelser for Tc-99m, som er derivater av bicyklo [2 . 2 . lj heptanbis (mety laminer) er funnet og er nyttige til visualisering av skjelettsystemet hos dyr. Disse nye kompleksdannende forbindelser er representert ved formel I ovenfor. Kompleksene går lett og effektivt gjennom nyrene og store mengder tas opp i benvevet. Forholdet mellom opptak i benvevet og det som tas opp i mykt vev, er stort. New stable complexing compounds for Tc-99m, which are derivatives of bicyclo [2 . 2. lj heptanebis (methylamines) have been found and are useful for visualizing the skeletal system in animals. These new complexing compounds are represented by formula I above. The complexes pass easily and efficiently through the kidneys and large amounts are taken up in the bone tissue. The ratio between absorption in the bone tissue and what is absorbed in soft tissue is large.
De nye kompleksdannende forbindelser ble funnet å danne stabile Tc-99m-komplekser når Sn ble tilsatt til en salt-vannsoppløsning som inneholdt kompleksdannere. Komplekset går lett gjennom nyrene og en stor mengde blir tatt opp i skjelettsystemet og svært lite blir tilbake i blodet og det bløte vev. The new complexing compounds were found to form stable Tc-99m complexes when Sn was added to a salt-water solution containing complexing agents. The complex passes easily through the kidneys and a large amount is absorbed into the skeletal system and very little remains in the blood and soft tissue.
Derfor, ettersom opptaket i benvev i forhold til i det om-sluttende bløte vev er stort, ble visualiseringen skarp og klar. Forholdet mellom aktiviteten i benvev/mykt vev og benvev/blod kommer gunstig ut i sammenligning med Tc-benvevsradiofarmaka som er i handelen. Therefore, as the absorption in bone tissue compared to that in the surrounding soft tissue is large, the visualization became sharp and clear. The ratio between the activity in bone tissue/soft tissue and bone tissue/blood comes out favorably in comparison with Tc bone tissue radiopharmaceuticals that are on the market.
De følgende eksempler illustrerer fremstilling og bruk av de nye forbindelser fremstilt ifølge oppfinnelsen. Identifika-sjon av forbindelsene er gjort med referanse til formel I ovenfor . The following examples illustrate the preparation and use of the new compounds produced according to the invention. Identification of the compounds is made with reference to formula I above.
Eksempel 1Example 1
Destillert vann (10 g) og H^PO-j (9,9 g) ble veid opp i en 50 ml rundkolbe utstyrt med en vannavkjølt kjøler, et termometer, en rørestav og en tilsetningstrakt. Konsentrert HC1 (11,8 g) ble deretter tilsatt og 3,9 g 2 ( 3) , 5 (6)-bis [aminometyl] bicyklo-(2,2,1)heptan ble sakte tilsatt under røring. Oppløsningen ble varmet med tilbakeiøp i omtrent én time og en 37 prosent vandig formaldehydoppløsning (8,51g) ble tilsatt i løpet av et tidsrom på 2,5 timer. Oppløsningen ble varmet i nok 3 timer med til- bakeløp. Forbindelsen som ble dannet var det fullstendig fos-fonometylerte norbornan-derivatet hvori hver av A, B, X og Y var metylenfosfonsyregrupper, -CH-jPO^B^ . Distilled water (10 g) and H 2 PO-j (9.9 g) were weighed into a 50 mL round bottom flask equipped with a water-cooled condenser, a thermometer, a stirring rod, and an addition funnel. Concentrated HCl (11.8 g) was then added and 3.9 g of 2(3),5(6)-bis[aminomethyl]bicyclo-(2,2,1)heptane was slowly added with stirring. The solution was refluxed for approximately one hour and a 37 percent aqueous formaldehyde solution (8.51g) was added over a period of 2.5 hours. The solution was heated for another 3 hours with reflux. The compound formed was the fully phosphonomethylated norbornane derivative in which each of A, B, X and Y were methylenephosphonic acid groups, -CH-jPO^B^ .
Eksempel 2Example 2
Fremgangsmåten i eksempel 1 ble fulgt ved tilsetning avThe procedure in example 1 was followed by the addition of
3 molekvivalenter formaldehyd (24,3 g av en 37 prosent oppløs-ning) og fosforsyrling (25,1 g) til én molekvivalent 2(3),5(6)-bis [aminometyl] bicyklo ( 2 , 2 ,1) heptan (15,2 g) . Den resulterende oppløsning ble nøytralisert med NaOH (aq) og én molekvivalent glykolonitril (14,7 g av en 38 prosent oppløsning) og NaOH (13,8 g av en 33,3 prosent oppløsning) ble tilsatt. Forbindelsen som ble dannet var natriumsaltet av bicykloheptanderivatet som hadde et gjennomsnitt på tre metylenfosfonsyregrupper og én karboksymetylgruppe pr. molekyl som A-, B-, X- og Y-substituenter . 3 molar equivalents of formaldehyde (24.3 g of a 37 percent solution) and phosphoric acid (25.1 g) to one molar equivalent of 2(3),5(6)-bis[aminomethyl]bicyclo(2,2,1)heptane (15.2g) . The resulting solution was neutralized with NaOH (aq) and one molar equivalent of glycolonitrile (14.7 g of a 38 percent solution) and NaOH (13.8 g of a 33.3 percent solution) was added. The compound formed was the sodium salt of the bicycloheptane derivative which had an average of three methylenephosphonic acid groups and one carboxymethyl group per molecule as A, B, X and Y substituents.
Eksempel 3Example 3
En mengde (15,2 g, 0,1 mol) 1 ( 2) , 4 (5)-bis [aminometyl] bicyklo ( 2 , 2 ,1) heptan ble fylt i et rustfritt stålbeger og 50 ml destillert vann ble tilsatt, etterfulgt av tilsetning av 37 ml 50 prosent NaOH. Denne oppløsningen ble varmet til rundt 70° under røring og karboksymetylering ble utført ved dråpevis tilsetning av 58,9 g 38 prosent glykolonitril mens oppvarmingen fortsatte, i løpet av et tidsrom på én time. Etter rundt 15 minutter av tilsetningen, var temperaturen ved tilbakeløp og NH ble frigjort. Destillert vann ble med jevne mellomrom tilsatt for å erstatte det fordampede vann. Etter at tilsetningen av glykolonitril var fullført, ble oppløsningen varmet i nok én time under røring og rensing med N^- Forbindelsen som ble dannet var tetrakarboksymety1-derivatet der A, B, X og Y var An amount (15.2 g, 0.1 mol) of 1(2),4(5)-bis[aminomethyl]bicyclo(2,2,1)heptane was placed in a stainless steel beaker and 50 ml of distilled water was added, followed by the addition of 37 ml of 50 percent NaOH. This solution was heated to about 70° with stirring and carboxymethylation was carried out by dropwise addition of 58.9 g of 38 percent glycolonitrile while heating continued, over a period of one hour. After about 15 minutes of the addition, the temperature was at reflux and NH was released. Distilled water was periodically added to replace the evaporated water. After the addition of glycolonitrile was complete, the solution was heated for another hour with stirring and purged with N^- The compound formed was the tetracarboxymethyl derivative where A, B, X and Y were
CH2-COONA. CH2-COONA.
Nytten av forbindelsene fremstilt ifølge oppfinnelsen ble fastslått ved å utføre tester på kjelestenshindring i henhold til National Association of Corrosion Engineers'(NACA) test-metode TM-03-74. Resultatene når det gjelder hindring av kaisiumkarbonat-kjeies ten er vist i tabell I og sammenlignet med et middel for å hindre kjelesten, som er i handelen, aminotri-(metylenfosfonsyre). Hindring av kalsiumsulfat-kjelesten ble også undersøkt og resultatene er vist i tabell II. The utility of the compounds of this invention was determined by performing boiler scale inhibition tests according to National Association of Corrosion Engineers' (NACA) test method TM-03-74. The calcium carbonate scale inhibition results are shown in Table I and compared with a commercially available scale inhibitor, aminotri-(methylenephosphonic acid). Inhibition of the calcium sulfate boiler was also investigated and the results are shown in Table II.
Nytten av forbindelsene fremstilt ifølge den foreliggende oppfinnelse når det gjelder å fungere som chelatdannende midler ble demonstrert ved å titrere forbindelsene med standard kobber-oppløsning i nærvær av kromazurol-S-indikator. Forbindelsen i eksempel 1 ble titrert og funnet å kompleksbinde omtrent 1,5 mol kobber pr. mol ligand. Denne forbindelsen kan fungere enten som en terskelforbindelse eller en chelatdannende forbindelse. The utility of the compounds prepared according to the present invention in acting as chelating agents was demonstrated by titrating the compounds with standard copper solution in the presence of chromazurol-S indicator. The compound in example 1 was titrated and found to complex approximately 1.5 mol of copper per moles of ligand. This compound can act either as a threshold compound or a chelating compound.
Det bør være klart at forbindelsene fremstilt ifølge oppfinnelsen kan ha flere forskjellige grupper som A-, B-, X- og Y-substituenter på det samme molekyl, men at når blandede derivater fremstilles er det ikke mulig å dirigere eller forutsi hvilket aminhydrogener som blir substituert. Produktet inneholder sannsynligvis en blanding av isomere forbindelser. It should be clear that the compounds prepared according to the invention can have several different groups such as A, B, X and Y substituents on the same molecule, but that when mixed derivatives are prepared it is not possible to direct or predict which amine hydrogens will be substituted. The product probably contains a mixture of isomeric compounds.
Mens alle forbindelsene vil chelatbinde metallioner, vil bare de som inneholder minst én metylenfosfonsyre-gruppe eller dets salt gi en terskeleffekt. While all compounds will chelate metal ions, only those containing at least one methylenephosphonic acid group or its salt will produce a threshold effect.
Eksempel 4Example 4
Ett hundre yl av oppløsningen fremstilt i eksempel 1 ble plassert i en ampulle og én ml 0,9 prosent saltoppløsning (aq) bie tilsatt. Oppløsningens pH ble justert til 3,5 ved å bruke fortynnet NaOH og HC1 og 0,1 ml av en nylig eluert TcO^ -opp-løsning ble tilsatt. Dette ble fulgt av tilsetning av 100 yl mettet tinn (II)tartrat-oppløsning. Utvasking av papirkromato-grafistrimler med saltoppløsning og aceton viste mindre enn 5 prosent aktivitet som TcO^eller redusert ikke kompleksbundet Tc. One hundred µl of the solution prepared in Example 1 was placed in a vial and one ml of 0.9 percent saline solution (aq) was added. The pH of the solution was adjusted to 3.5 using dilute NaOH and HCl and 0.1 ml of a freshly eluted TcO₂ solution was added. This was followed by the addition of 100 µl of saturated tin (II) tartrate solution. Leaching of paper chromatography strips with saline and acetone showed less than 5 percent activity as TcO 3 or reduced uncomplexed Tc.
Tc-komplekset ovenfor (50 ul,~lmCi) ble injisert i nåle-venen på rotter. Scintilleringsscanning av de bedøvede rotter bie tatt ved flere tidspunkter etter injeksjonen. Benvevs-scanningen var av høy kvalitet, noe som medfører bruken av dette som et redskap for menneske-pasienter. The above Tc complex (50 µl,~lmCi) was injected into the needle vein of rats. Scintillation scanning of the anesthetized rats bee taken at several time points after the injection. The bone tissue scan was of high quality, which entails the use of this as a tool for human patients.
Eksempel 5Example 5
Tc-kompleksene som ble fremstilt i eksempel 4 (50 yl, -lmCi) ble injisert i halevenen på mus. Musene ble drept på forskjellige tidspunkter etter injeksjonen, organene og vevet ble fjernet, og strålingen målt med en Nal-teller. Aktiviteten bie funnet primært i benvevet og blæren mens ingen andre organer viste noen stor affinitet for komplekset. 120 Minutter etter injeksjonen hadde benvevet, musklene og leveren henholdsvis 5,1<0,01 og 0,24 prosent dose/g av aktiviteten. The Tc complexes prepared in Example 4 (50 µl, -1mCi) were injected into the tail vein of mice. The mice were killed at various times after the injection, the organs and tissues were removed, and the radiation was measured with a Nal counter. The activity was found primarily in the bone tissue and the bladder, while no other organs showed any great affinity for the complex. 120 Minutes after the injection, the bone tissue, muscles and liver had respectively 5.1<0.01 and 0.24 percent dose/g of the activity.
Eksempel 6Example 6
Tc-komplekset i eksempel 4 (50 yl, -lmCi) ble injisert i halevenen på en rekke rotter. Dyrene ble drept etter 2 timer og strålingen fra flere vev ble målt kvantitativt ved å bruke en Nal scintillerings-teller. Tabell III under, viser resultatene sammenlignet med Tc-MDP (metylendifosfonat), Tc-benvevs-middel i handelen, målt på identisk måte. The Tc complex of Example 4 (50 µl, -1mCi) was injected into the tail vein of a number of rats. The animals were killed after 2 hours and the radiation from several tissues was measured quantitatively using a Nal scintillation counter. Table III below shows the results compared to Tc-MDP (methylene diphosphonate), the commercial Tc bone tissue agent, measured in an identical manner.
Eksempel 7 Example 7
Komplekset fra eksempel 4 ble injisert i ørevenen på en rekke kaniner. Kaninene ble drept i løpet av 3 timer etter injeksjonen. Strålingen i flere vev ble målt kvantitativt ved telling med bruk av en Nal scintilleringsteller. Tabell IV nedenfor viser resultatene sammenlignet med de fra et Tc-ben-vevsmiddel i handelen, MDP. The complex from Example 4 was injected into the ear vein of a number of rabbits. The rabbits were killed within 3 hours of the injection. The radiation in several tissues was measured quantitatively by counting using a Nal scintillation counter. Table IV below shows the results compared to those of a commercial Tc bone tissue agent, MDP.
Scintillerings-scanning av kaninene ovenfor, 2 timer etter injeksjonene med komplekset fra eksempel 4, falt gunstig ut i sammenligning med de hvor det ble brukt Tc-MDP-sett som er i handel. Scintillation scanning of the above rabbits, 2 hours after the injections with the complex of Example 4, compared favorably with those using commercial Tc-MDP kits.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO901139A NO901139D0 (en) | 1984-02-27 | 1990-03-12 | PROCEDURE FOR AA PREVENTING THE EXPOSURE OF METAL IONS FROM THEIR Aqueous SOLUTIONS. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/584,070 US4508704A (en) | 1984-02-27 | 1984-02-27 | Radioactive metals complexed with phosphonate derivatives of bicycloheptane bis(alkylamines) |
US06/584,071 US4500469A (en) | 1984-02-27 | 1984-02-27 | Metal ion control compounds based on norbornane |
NO850777A NO169011C (en) | 1984-02-27 | 1985-02-26 | NEW BIS (AMINOMETHYL) BICYCLO (2.2.1.) HEPTANES FOR DIAGNOSTIC USE, AND BONE-TREAT-SEARCH COMPLEXES OF A RADIOACTIVE NUCLIDE AND THEIR HEPTANES |
NO901139A NO901139D0 (en) | 1984-02-27 | 1990-03-12 | PROCEDURE FOR AA PREVENTING THE EXPOSURE OF METAL IONS FROM THEIR Aqueous SOLUTIONS. |
Publications (2)
Publication Number | Publication Date |
---|---|
NO901139L true NO901139L (en) | 1985-08-28 |
NO901139D0 NO901139D0 (en) | 1990-03-12 |
Family
ID=27484107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO901139A NO901139D0 (en) | 1984-02-27 | 1990-03-12 | PROCEDURE FOR AA PREVENTING THE EXPOSURE OF METAL IONS FROM THEIR Aqueous SOLUTIONS. |
Country Status (1)
Country | Link |
---|---|
NO (1) | NO901139D0 (en) |
-
1990
- 1990-03-12 NO NO901139A patent/NO901139D0/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO901139D0 (en) | 1990-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4898724A (en) | Organis amine phosphonic acid complexes for the treatment of calcific tumors | |
US4560548A (en) | Bone seeking Tc-99m complexes of phosphonate derivatives of bis(aminoalkyl)piperazine | |
US4115541A (en) | Bone-seeking technetium-99m complex | |
US4606907A (en) | Bone seeking Tc-99m complexes of phosphonate derivatives of polyamidoamines | |
US3989730A (en) | Bone-seeking technetium-99m complex | |
Nash et al. | Calorimetric and laser induced fluorescence investigation of the complexation geometry of selected europium-gem-diphosphonate complexes in acidic solutions | |
DK149642B (en) | PREPARING FOR THE PREPARATION OF 99MTEKNETIUM RADIODIAGNOSTICS | |
US4032625A (en) | Bone-seeking technetium-99m complex | |
US5066478A (en) | Radio labeled organic amine phosphonic acid complexes for the treatment of calcific tumors | |
US4515767A (en) | Radioactive metals complexed with phosphonate derivatives of dicyclopentadienebis(methylamine) | |
Claessens et al. | Stability constants of tin (II) and calcium diphosphonate complexes | |
NO901139L (en) | PROCEDURE FOR AA PREVENTING THE EXPOSURE OF METAL IONES FROM THEIR Aqueous SOLUTIONS. | |
NO169011B (en) | NEW BIS (AMINOMETHYL) BICYCLO (2.2.1.) HEPTANES FOR DIAGNOSTIC USE, AND BONE-TREAT-SEARCH COMPLEXES OF A RADIOACTIVE NUCLIDE AND THEIR HEPTANES | |
GB1564049A (en) | Diphosphonoalkane carboxylic acids | |
NO901138L (en) | PROCEDURE FOR AA CHELAT BOND METAL IONS IN A SOLUTION SOLUTION THEREOF. | |
US4508704A (en) | Radioactive metals complexed with phosphonate derivatives of bicycloheptane bis(alkylamines) | |
CA1236481A (en) | Metal ion control compounds based on norbornane | |
EP0166020B1 (en) | New metal ion control agents based on dicyclopentadiene derivatives | |
EP0176288A1 (en) | Aminocarboxylic acid complexes for the treatment of calcific tumors | |
Choppin et al. | Thermodynamics of lanthanide TMEDTA complexation | |
US4568468A (en) | Use of norbornane derived compounds as threshold agents | |
Kevill et al. | Elimination Reactions of α-Halogenated Ketones. X. 1a Extent of Concurrent Substitution Reaction Accompanying Chloride Ion-promoted Elimination from 2-Benzyl-2-halogeno-4, 4-dimethyl-l-tetralones in Solvent Acetonitrile | |
EP0138384B1 (en) | Imaging cardiac infarcts with radioactive metals complexed with phosphonate derivatives | |
US3984531A (en) | Technetium-99m-tin-monofluorophosphate complex | |
Kristiansen | Radiochemical analysis of cadmium in nitric and phosphoric acid |